Overview

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Status:
Recruiting
Trial end date:
2025-06-26
Target enrollment:
Participant gender:
Summary
This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).
Phase:
Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Ocrelizumab